Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;82(7):850-857.
doi: 10.1002/pros.24327. Epub 2022 Mar 3.

Hereditary cancer risk assessment and genetic testing in the community urology practice setting

Neal D Shore  1 , Lauren Lenz  2 , Elizabeth S Cogan  2 , Diana Iliev  2 , Lizzie Spencer  2 , Darl D Flake 2nd  2 , Stephanie Meek  2 , Thaylon Davis  2 , Karen Copeland  2 , Robert Finch  2 , William Schiff  3 , Howard Korman  4 , Manoj Rao  5 , Laurence Belkoff  6 , Mark Jalkut  7 , Neil Mariados  8 , Richard D'Anna  9 , Bryan Mehlhaff  10 , Thomas P Slavin  2 , Todd D Cohen  2
Affiliations

Hereditary cancer risk assessment and genetic testing in the community urology practice setting

Neal D Shore et al. Prostate. 2022 May.

Abstract

Objectives: To evaluate the feasibility of integrating a hereditary cancer risk assessment (HCRA) process in the community urology practice setting for patients with prostate cancer (PCa).

Methods: In this prospective intervention, an HCRA process was implemented across six different community urology clinics between May 2019 and April 2020. The intervention included a process integration during which the workflow at each site was refined, a post-integration period during which HCRA was conducted in all patients with PCa, and a follow-up period during which healthcare providers and patients reported their satisfaction with the HCRA and genetic testing process.

Results: Among patients who completed a family history assessment during the post-integration period, 23.6% met guideline criteria for genetic testing. Of all patients seen at the clinic during the post-integration period, 8.7% completed genetic testing; this was a twofold increase over the period immediately preceding process integration (4.2%), and a sevenfold increase over the same period 1 year prior (1.2%). The majority of providers reported that the HCRA was as important as other regularly performed assessments (61.0%) and planned to continue using the process in their practice (68.3%). Most patients believed that the genetic test results were important for their future cancer care (84.7%) and had already shared their test results with at least one family member (63.2%).

Conclusions: This study demonstrated that implementing an HCRA process in the community urology practice setting was feasible, generally favored by providers and patients, and resulted in an increase in the number of patients with PCa who completed genetic testing.

Keywords: genetic testing; hereditary cancer; prostate cancer.

PubMed Disclaimer

References

REFERENCES

    1. Page EC, Bancroft EK, Brook MN, et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019;76(6):831-842.
    1. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106(10):1697-1701.
    1. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443-453.
    1. Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141-149.
    1. Haraldsdottir S, Hampel H, Wei L, et al. Prostate cancer incidence in males with Lynch syndrome. Genet Med. 2014;16(7):553-557.

Publication types

LinkOut - more resources